Heart failure & cardiomyopathies
Cost-effectiveness of an antibacterial envelope for infection prevention in patients undergoing cardiac resynchronization therapy reoperations in Denmark
Main finding · ICER, CRT reoperationsResult — go to the resultICER €12 022 per QALYAuthors' conclusion
Cost-effectiveness ratios were favourable for patients undergoing CRT reoperations in the Danish healthcare system, and thus are in line with previous studies.
Study context
- Population
- Infection-risk patients undergoing cardiac resynchronization therapy (CRT) reoperations, Denmarktwo-centre cohort
- Participants
- 1,943 patients
- Exposure
- Antibacterial envelope vs standard-of-care IV antibiotics
- Outcome
- Costs per QALY (ICER); threshold €34 125/QALY gained
Methodological detailsdecision-tree model, decision-tree-based model, Danish observational two-centre cohort data
- Decision-tree model
- Decision-tree-based model
- Danish observational two-centre cohort data
Main finding
ICER, CRT reoperations
Incremental cost-effectiveness ratio (ICER)
€12 022 per QALY
As reported in the abstract
Observational data: associations, not effects.
Further findings
ICER by device type (subgroup)
- ICER, CRT defibrillator
- €6227 per quality-adjusted life year (QALY) gained
- ICER, CRT pacemaker
- €29 177 per QALY gained
Original publication
Cost-effectiveness of an antibacterial envelope for infection prevention in patients undergoing cardiac resynchronization therapy reoperations in Denmark. Europace. Published 22 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →